Hepatitis B virus (HBV) is designated a "metabolovirus" due to the intimate connection between the virus and host metabolism. The nutrition state of the host plays a relevant role in the severity of HBV infection. Metabolic syndrome (MS) is prone to increasing HBV DNA loads and accelerating the progression of liver disease in patients with chronic hepatitis B (CHB). Cluster of differentiation 36 (CD36), also named fatty acid translocase, is known to facilitate long-chain fatty acid uptake and contribute to the development of MS. We recently found that CD36 overexpression enhanced HBV replication. In this study, we further explored the mechanism by which CD36 overexpression promotes HBV replication. Our data showed that CD36 overexpression increased HBV replication, and CD36 knockdown inhibited HBV replication. RNA sequencing found some of the differentially expressed genes were involved in calcium ion homeostasis. CD36 overexpression elevated the cytosolic calcium level, and CD36 knockdown decreased the cytosolic calcium level. Calcium chelator BAPTA-AM could override the HBV replication increased by CD36 overexpression, and the calcium activator thapsigargin could improve the HBV replication reduced by CD36 knockdown. We further found that CD36 overexpression activated Src kinase, which plays an important role in the regulation of the store-operated Ca channel. An inhibitor of Src kinase (SU6656) significantly reduced the CD36-induced HBV replication. We identified a novel link between CD36 and HBV replication, which is associated with cytosolic calcium and the Src kinase pathway. CD36 may represent a potential therapeutic target for the treatment of CHB patients with MS.
Introduction
Hepatitis B virus (HBV) is a small DNA virus that predominately infects liver cells and is the most common cause of hepatitis, cirrhosis and hepatocellular carcinoma [1] . It is also designated a "metabolovirus" due to the intimate connection between the virus and host metabolism [2] . HBV transcription and replication is regulated mainly by the recruitment of a variety of cellular transcription factors to its promoters and enhancers, some of which are linked to host metabolic processes [3] . Several epidemiological studies demonstrated that the individual diet and host nutrition state play relevant roles in the severity of HBV infection [4] . Starvation and fasting increased HBV transcription and gene expression [5] . Bile acids also increased HBV transcription and gene expression in vitro experiments [6] . Host cholesterol was an essential element for HBV assembly and viral infection [7, 8] . These results suggested that the host metabolic changes generate a permissive milieu that may be advantageous to the HBV life cycle.
The number of chronic hepatitis B (CHB) patients with concomitant metabolic diseases has increased gradually. A recent study reported that 13% of CHB patients had metabolic syndrome (MS), and the prevalence of liver cirrhosis was higher in CHB patients with MS (38%) than those without MS (11%) [9] . A population-based study showed that CHB patients with MS had significantly higher levels of HBV DNA loads compared to those without MS [10] . High viral load is considered an important risk factor for the development of liver cirrhosis and hepatocellular carcinoma in CHB patients. Therefore, further exploration of the hepatic metabolic factors that control HBV replication may be an important step in the treatment strategies for CHB patients with MS.
Cluster of differentiation 36 (CD36), also named fatty acid translocase, belongs to the scavenger receptor family and is a transmembrane glycoprotein found on the surface of many cell types in vertebrates [11] . It is a facilitator of long-chain fatty acid transport and other biologically active lipids, such as ox-LDL. With many ligands and functions, CD36 could have an influence on various conditions associated with MS, atherosclerosis and non-alcoholic fatty liver disease (NAFLD) [12] . The expression of CD36 was weak in the normal liver, but a mouse model showed that its expression was significantly increased during high fatty acid feeding [13] . Clinical studies also exhibited higher soluble CD36 in patients with NAFLD and MS [14, 15] . Recent studies demonstrated that a chronic HBV immune tolerant phase characterized by high levels of HBV replication had higher levels of free fatty acids compared with healthy controls [16] . In addition, elevated levels of total fatty acids are clearly induced in the HBVreplicating cell line HepG2.2.15 [17] . However, whether CD36 is a molecular bridge between fatty acid metabolism and HBV replication is largely unknown.
Our previous study found that the expression of CD36 was increased in the HBV-replicating cell line, and CD36 overexpression enhanced HBV replication, but the mechanism is still unknown [18] . In this study, we aimed to investigate the molecular mechanism by which CD36 overexpression enhanced HBV replication.
Materials and methods

Cell culture and construction
HepG2.2.15 and HepAD38 cells were cultured in modified Eagle's medium (MEM) containing 10% fetal calf serum and 500 µg/mL G418. To stably overexpress CD36 in HepG2.2.15 and HepAD38 cells, a human CD36 overexpression lentivirus system was constructed, packaged, and purified by GeneChem (Shanghai, China). CD36-overexpression-lentivirus and vector-lentivirus were transfected into HepG2.2.15 and HepAD38 cells according to the manufacturer's protocol. To generate CD36 knockdown cells, a lentivirus system expressing CD36 shRNA was constructed by GeneChem. The CD36 shRNA targeting sequence was as follows: 5′-GGCTGTGTTTGGAGGTATTCT-3′. CD36-shRNA-lentivirus and scramble control-lentivirus were transfected into HepG2.2.15 and HepAD38 cells according to the manufacturer's protocol.
Purification and quantification of core particles associated with HBV DNA from HBV-replicating cells
Core particles associated with HBV DNA were extracted from equal numbers of cells 96 h after transfection. Cells were collected, and cell number was counted using an Innovatis Cedex XS Analyzer (Roche, Bielefeld, Germany). Next, cells were washed with PBS and lysed with 500 µL of lysis buffer (50 mM Tris-HCl (pH 7.4), 1 mM EDTA, 1% NP-40) at room temperature for 30 min. Cell nuclei were pelleted by centrifugation for 1 min at 10,000 g. Then, the supernatant was treated with 60 U of DNase I and 10 mM MgCl 2 for 4 h at 37°C and centrifuged again. The supernatant was supplemented with 200 µL of 35% PEG8000 containing 1.5 M NaCl and rested on ice for 40 min. Then, the pellet of the virus core particles was collected after centrifugation at 12,000 g for 5 min at 4°C. The virus core particles were digested overnight at 42°C in 500 µL digestion buffer (0.5 mg/ mL proteinase K, 25 mM Tris-HCl (pH 8.0), 0.5% SDS, 150 mM NaCl, and 10 mM EDTA). HBV DNA in the digestion mixture was extracted twice with phenol-chloroform (1:1), precipitated with ethanol and glycogen, and dissolved in ddH 2 O. HBV DNA was analyzed by southern blot (DIG-High Prime DNA Labeling and Detection Starter Kit II, Roche, Rotkreuz, Switzerland) and real-time PCR using the SYBR Green method (Takara, Dalian, China). The forward and reverseprimers were as follows:
5′-TGCGGCGTTTTATCATATTCC −3′ and 5′-ATACCTTGGTAGTCCAGAAGAACCA-3′, respectively.
To determine the effect of chemical reagents on the process of CD36 affecting HBV replication, CD36 overexpression cells were treated with calcium chelator BAPTA-AM (Selleck, Houston, TX, USA) at a concentration of 25 μM and Src family kinase inhibitor SU6656 (Selleck, Houston, TX, USA) at a concentration of 0.6 μM, and CD36 knockdown cells were treated with calcium mobilizing agent thapsigargin (SigmaAldrich, St. Louis, MO, USA) at a concentration of 5 nM and 2.5 nM in HepAD38 and HepG2.2.15, respectively. After 96 h, the HBV DNA was extracted and measured by real-time PCR, as described above. Cell viability under each condition was assayed by using trypan blue.
Measurement of the secreted HBsAg and HBeAg
The concentrations of HBV surface antigen (HBsAg) and HBV e antigen (HBeAg) in the culture medium were detected by the enzymelinked immunosorbent assay (ELISA) kit (KHB, Shanghai, China) according to the manufacturer's protocols.
Animal study
To build the mouse model of acute hepatitis B virus infection, 9-week-old male C57BL/6 wild type (WT) and CD36 knockout (CD36KO) mice were used. CD36KO mice created on a C57BL/6 background were kindly provided by Dr. Maria Febbraio (Lerner Research Institute, U.S.). All animal studies were conducted according to the protocol approved by the Institutional Animal Care and Use Committee at Chongqing Medical University. A total of 20 μg of pGEM-HBV1.3 plasmid was injected into the tail veins of mice in a volume of saline equivalent to 8% of the mouse body weight within 5-8 s. The serum and liver tissue samples were collected on the fifth day. The levels of HBsAg and HBeAg were measured by chemiluminescence immunoassay (Abbott Architect, USA). HBV DNA in the serum and liver was extracted using the Hipure viral DNA mini kit (Magen, Guangzou, China) and measured by real-time PCR, as described above. The HBV core protein of liver tissue was visualized by immunohistochemical staining using anti-HBc antigen antibody (1:100, Abcam, Cambridge, UK). To determine the role of calcium reagents in reducing and elevating cytosolic calcium, CD36 overexpression cells were treated with calcium chelator BAPTA-AM at a concentration of 25 μM, and CD36 knockdown cells were treated with calcium mobilizing agent thapsigargin at concentrations of 5 nM and 2.5 nM in HepAD38 and HepG2.2.15, respectively. After 48 h, the concentration of intracellular calcium was measured, as described above. Cell viability under each condition was assayed using trypan blue.
Cytosolic calcium analysis
Western blotting
Cells were lysed using RIPA containing a protease inhibitor cocktail and phosphatase inhibitor cocktail, and the protein content was measured and normalized using a BCA protein assay kit. Total proteins (50 µg) were separated by SDS-PAGE and transferred onto PVDF membranes. After blocking with 3% BSA, the membranes were incubated with primary antibodies: anti-CD36, 1:2000 (Abcam, Cambridge, UK); anti-Src, anti-p-Src, 1:2000 (CST, Danvers, MA, USA); anti-actin, 1:4000, (ProteinTech, Wuhan, China), at 4°C overnight and subsequently incubated with the corresponding horseradish peroxidase (HRP)-conjugated secondary antibodies. Finally, the blot was detected using an ECL advance western blotting detection kit (Millipore, Temecula, CA, USA). The protein signal intensity was analyzed using ImageJ software (National Institutes of Health, USA).
Measurement of the production of Inositol 1,4,5-Triphosphate (IP3) by ELISA
Cells were cultured in a 10-cm plate. IP3 was extracted from equal numbers of cells at 72 h. IP3 levels in the cytoplasm were measured with a human IP3 ELISA kit (SinoBestBio, Shanghai, China).
Statistics
Experimental data are shown as the means ± standard deviations. The t-test was applied to comparisons between different groups; values of P < 0.05 were considered to indicate statistical significance. Statistical analysis was performed using GraghPad Prism software.
Results
CD36 overexpression promoted HBV replication in vitro
HepG2.2.15 and HepAD38 cells, which support stable HBV replication, protein expression, and virion assembly and secretion, were infected with recombinant lentivirus expressing CD36 cDNA to obtain stable CD36 overexpression (CD36OE) cell line models. There were significant increases in CD36 protein levels in the CD36OE group compared with in the vector group (Fig. 1A) , suggesting that CD36 overexpression was successfully established in both cell lines. HBV DNA replicative intermediates were detected by both real-time PCR and southern blot. The data showed that CD36 overexpression induced significantly elevated levels of HBV DNA in both cell lines (Fig. 1B and  C) . Meanwhile, CD36 overexpression significantly elevated the levels of HBsAg and HBeAg compared with those in the vector group (Fig. 1C) . These data suggested that CD36 overexpression could enhance HBV replication.
CD36 knockdown inhibited HBV replication in vitro and in vivo
As shown in Fig. 2A, CD36 expression was efficiently downregulated in shRNA-targeting CD36 (shCD36) compared with shRNAscramble control (shCont) in both HepG2.2.15 and HepAD38 cells, suggesting that stable CD36 knockdown cell lines were successfully established. CD36 knockdown resulted in decreased levels of HBV DNA replicative intermediates in both cells (Fig. 2B and C) . Gene silencing of CD36 significantly inhibited HBsAg and HBeAg secretions (Fig. 2C) . These data suggested that CD36 knockdown inhibited HBV replication.
In an acute HBV infection mouse model, the serum HBsAg and HBeAg levels were significantly decreased in CD36 knockout (CD36 KO) mice compared with in wild type (WT) mice (Fig. 2D) . Moreover, the levels of HBV DNA in the serum and liver were remarkably decreased in CD36 KO mice compared with in WT mice (Fig. 2D) . The expression of HBcAg in livers from the two groups of mice was detected by immunohistochemical staining. The frequency of HBcAgpositive hepatocytes decreased significantly in CD36 KO mice compared with in WT mice (Fig. 2D) . These data in vivo were similar to those in vitro.
CD36 expression affected the levels of cytosolic calcium in vitro
To explore the molecular mechanism by which CD36 affects HBV replication, we performed RNA sequencing of the mRNA from HepG2.2.15-CD36OE cells and HepG2.2.15-vector cells to understand the differential transcriptomic profile. Our results showed that some of the differentially expressed genes, such as KCNK10, SCN9A, and S100A3, were involved in the potassium voltage-gated channel, sodium voltage-gated channel and calcium binding protein (Fig. 3A) . Next, we specially focus on the potential role of CD36 in calcium ion homeostasis, which supports HBV replication and assembly, as shown in previous studies [19, 20] . We found that CD36 overexpression significantly increased the levels of cytosolic calcium and CD36 knockdown decreased the levels of cytosolic calcium, as evidenced by flow cytometry (Fig. 3B and C) , suggesting that CD36 expression affected the levels of cytosolic calcium in both HepG2.2.15 and HepAD38 cells.
Cytosolic calcium signals involved in CD36-mediated regulation of HBV replication in vitro
Furthermore, the data showed that the calcium chelator BAPTA-AM reduces cytosolic calcium in CD36 overexpression cells (Fig. 4A) , while the calcium mobilizing agent thapsigargin increases cytosolic calcium in shCD36 cells (Fig. 4B) . The levels of HBV DNA were decreased in the BAPTA-AM-treated CD36OE group compared with in the untreated group, and the levels of HBV DNA were increased in thapsigargin treated shCD36 cells (Fig. 4A and B) , suggesting that CD36 was implicated in HBV replication by cytosolic calcium.
CD36 overexpression enhanced HBV replication by activating Src kinase
CD36 has been linked to the phosphorylation of Src kinases, which play an important role in the regulation of calcium influx [21, 22] . The activity of Src kinases is regulated by the phosphorylation at the Tyr416 site in the activation loop domain to upregulate enzyme activity [23] . We investigated the effect of CD36 overexpression on the activity of Src kinase in HepG2.2.15 and HepAD38 cells. The data demonstrated that CD36 overexpression enhances the Tyr416 phosphorylation of Src kinase in both cells (Fig. 5A) . Previous studies suggested that the activation of Src kinase could enhance calcium released from the endoplasmic reticulum pool to increase the free intracellular calcium concentrations by an inositol 1,4,5-triphosphate(IP3)-dependent mechanism [24] . Here, CD36 overexpression elevates the levels of cytoplasm IP3 compared with vector control cells (Fig. 5B) . We further investigated the role of Src kinase in the CD36-induced HBV replication using a selective inhibitor of Src kinase SU6656. Our data showed that the Src kinase inhibitor SU6656 significantly diminished the CD36-induced increases of IP3, cytosolic calcium and HBV replication in both CD36 overexpression cells (Fig. 5B, C and D) . These results suggest that CD36 overexpression facilitated the phosphorylation of Src kinase to regulate HBV replication.
Discussion
HBV is an enveloped DNA virus that requires host lipid for the viral envelope and surface antigen particles [25, 26] . The dysregulated lipid profile and altered lipid-related genes are likely due to metabolic hijacking by HBV in favor of its viral replication. A study demonstrated that fatty acid synthase (FAS) was upregulated in HBV-infected cells and the reduction of FAS by siRNA would suppress viral replication [27] . Recently, the relationship between fatty acid translocase CD36 and HBV has aroused our concern.
CD36 has been reported to facilitate Hepatitis C virus (HCV) entry in favor of viral replication, and blocking CD36 inhibited HCV replication [28] . Several studies have suggested that CD36 contributed to virion release in human immunodeficiency virus (HIV)-infected macrophages, and CD36 silenced or inhibited by soluble anti-CD36 antibodies showed decreasing quantities of HIV virions released [29] . Our previous study demonstrated that CD36 overexpression enhanced HBV replication in HepG2.215 cells [18] . Here, we found the same results in another HBV expression cell line, HepAD38 cells, which are derived from HepG2 and can replicate HBV under the control of the inducible tetracycline promoter. HepAD38 cells produce higher levels of viral DNA by approximately 11-fold compared with HepG2.2.15 cells [30] . Given these facts, an advantage of using HepAD38 cells is that HBV DNA replicative intermediates are easier to detect compared with HepG2.2.15 cells. This will be especially important in assessing antiviral effects in different cell lines to acquire relatively stable data, so the two cell lines were assessed in this study. We examined the effect of the depletion of CD36 on HBV replication and found that the suppression of CD36 possessed antiviral properties in both cell lines. These results suggest that the protein levels of CD36 are implicated in HBV replication in vitro.
HBV transgenic mice have been widely used in the functional studies of HBV replication and anti-HBV drugs [31, 32] . However, the production of transgenic mice is very ambitious and expensive. Hydrodynamic injection is a rapid, efficient and convenient gene delivery method for in vivo transfection that has widely been used to generate acute HBV infection models via the hydrodynamic injection of HBV DNA plasmid [33, 34] . In the present study, we successfully established an acute HBV infection mouse model via hydrodynamic injection and found that CD36 knockout mice had lower levels of HBV replication than wild type mice. The data corresponded with the cell experiments, strongly suggesting that CD36 plays an important role in regulating HBV replication.
With the development of transcriptome sequencing technology and bioinformatics, the RNA sequencing approach based on next-generation sequencing technology has been developed as a powerful tool for transcriptome analysis [35] . To understand the underlying molecular basis linking CD36 and HBV replication, we performed RNA sequencing of the mRNA from CD36 overexpression and the vector control HepG2.2.15 cells to analyze the differential transcriptomic profiles. Our results identified 141 differentially expressed genes in response to CD36 overexpression [18] . Unfortunately, the expression of cellular transcription factors related to HBV replication was not significantly different between the two groups. Then, we focused on some of the differentially expressed genes involved in ion channels and homeostasis. Our data suggested that CD36 overexpression affected ion homeostasis, especially calcium ion homeostasis, which plays an important role in HBV replication and assembly. Calcium homeostasis is essential for maintaining normal cell function and small as the changes in cytosolic calcium levels might be affect the cellular processes [36] . Many viruses could regulate intracellular calcium signals by encoding virus proteins to stimulate the viral replication of HIV, adenovirus, and Rubella virus [37, 38] . For HBV, various studies have suggested that HBV x protein (HBx) elevated the basal cytosolic calcium level, which was associated with HBV replication in HepG2 cells and cultured primary rat hepatocytes . HBV DNA levels in the serum and liver were detected by real-time PCR (n = 4) (*P < 0.05, **P < 0.01). HBV core protein expression in the liver of HBV-infected WT and CD36KO mice was visualized by immunohistochemistry using anti-HBcAg; arrows indicate HBcAg. [39, 40] . The HBx-deficient sample significantly decreased HBV replication and could be rescued by simply increasing cytosolic calcium levels [19] (SOC) channels [42] . Multiple studies have revealed that linoleic acid or palmitate is implicated in the phosphorylation of Src kinase by binding to CD36. Consequently, this phosphorylation induces the production of IP3, which leads to endoplasmic reticulum Ca 2+ depletion and is followed by the triggering of calcium influx into cells to bring about a large increase in cytosolic calcium via SOC channels [24, 43] . Several studies have suggested that HBx stimulates high levels of viral replication by stimulating polymerase activity via the activation of Src kinase and that blocking Src kinase could impair viral replication [44] . In this study, we found that high expression levels of CD36 improved the levels of Src kinase phosphorylation and the production of IP3. SU6656 as a commonly used inhibitor for Src kinase, could inhibit phosphorylation of Src kinase and the following calcium signaling pathways [45] . The Src kinase inhibitor SU6656 reduced IP3 secretion and cytosolic calcium levels, with a corresponding decrease of HBV replication, suggesting that CD36 regulated HBV replication via the Src kinase phosphorylation pathway.
Conclusions
In general, we have characterized new aspects of fatty acid translocase CD36 biology in HBV replication by showing that CD36 overexpression and knockdown are positive and negative regulators of HBV replication via cytosolic calcium and the Src kinase pathway, respectively. Given the relationship between CD36 and HBV replication, we hypothesize that for those HBV-infected patients with a higher expression level of CD36, such as NAFLD and MS patients, targeting CD36 may serve as an adjunctive therapeutic means for conventional anti-viral drugs. For now, it is still unclear whether CD36 is involved in other steps of the HBV life cycle, including virus entry and secretion. Further experiments will be needed to reveal the contribution of CD36 to the HBV life cycle.
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